Cornerstone Select Advisors’s TG Therapeutics TGTX Stock Holding History

Cornerstone Select Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.56M	Sell	46,908 -7,177	-13%	-$214K	0.98%	36
2025 Q4	$1.61M	Sell	54,085 -1,199	-2%	-$39.2K	1.12%	34
2025 Q3	$2M	Buy	55,284 +2,280	+4%	+$75.1K	1.47%	24
2025 Q2	$1.91M	Sell	53,004 -3,298	-6%	-$123K	1.68%	18
2025 Q1	$2.22M	Sell	56,302 -6,968	-11%	-$234K	2.1%	9
2024 Q4	$1.9M	Buy	+63,270	New	+$1.82M	1.84%	12

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Cornerstone Select Advisors's TGTX Position: Q1 2026 in Review

Cornerstone Select Advisors reduced its TG Therapeutics (TGTX) stake by 13% in Q1 2026, selling an estimated $214K and leaving 46,908 shares worth $1.56M. The position accounts for 0.98% of the portfolio, ranked #36.

Cornerstone Select Advisors first reported a position in TGTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.22M in Q1 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Cornerstone Select Advisors held 46,908 shares of TG Therapeutics worth $1.56M as of Q1 2026.
Cornerstone Select Advisors sold 7,177 TG Therapeutics shares in Q1 2026, an estimated $214K.
TG Therapeutics made up 0.98% of Cornerstone Select Advisors's portfolio in Q1 2026, its #36 holding.
Cornerstone Select Advisors first reported a position in TG Therapeutics in Q4 2024 and has held it in 6 quarters since.
Cornerstone Select Advisors's TG Therapeutics position peaked at $2.22M in Q1 2025.
363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Cornerstone Select Advisors's 13F filing for Q1 2026, filed 13 May 2026.